FDA Grants Priority Review to Belite Bio's Tinlarebant for Stargardt Disease, PDUFA Date Set for Feb 2027
BLTE has more than doubled off its 52-week low of $60.
Summary
The FDA accepted Belite Bio's NDA for tinlarebant in Stargardt disease type 1 and granted Priority Review, with a PDUFA date of February 12, 2027. This follows the NDA submission in June and positive Phase 3 data presented in July. Priority Review signals the FDA sees tinlarebant as a potential significant improvement over existing options for this rare retinal disease with no approved treatment. The accelerated timeline puts a definitive catalyst on the calendar, de-risking the regulatory path and bringing a potential first-to-market therapy closer to patients.
At the time of this announcement, BLTE was trading at $180.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $60.00 to $200.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.